Hematologic Oncology

Amit K. Verma, MD, spotlights new agents that have entered the myelodysplastic syndrome treatment arsenal and novel combinations currently under exploration, as well as efforts that are showing promise in patients with acute myeloid leukemia.

The panel considers the development, morbidity, and survival of transplant-associated thrombotic microangiopathy associated with GVHD (graft-versus-host disease).

Pharmacodynamic and pharmacokinetic modeling of the investigational MASP-2 inhibitor narsoplimab supported a weight-based dosing method for patients with hematopoietic stem cell transplant–associated thrombotic microangiopathy.

In December 2020, the FDA approved selinexor in combination with the proteasome inhibitor bortezomib and dexamethasone for patients with MM who have received at least 1 prior therapy.

Srdan Verstovsek, MD, PhD, briefly reviews the role of pacritinib in patients with myelofibrosis as well as the PACIFICA study.

Mendel Goldfinger, MD, discusses some of the key points of the ECHELON-1 trial data.

Jessica K. Altman, MD, reviews the safety and efficacy of gilteritinib as seen in the ADMIRAL trial for the treatment of relapsed/refractory acute myeloid leukemia.

Leukemia experts discuss the role of genetic testing to check for FLT3 mutations at the time of relapse in acute myeloid leukemia.

Experts discuss the role of transplant and evaluating options in patients with myelofibrosis. 

Ulrich Steidl, MD, PhD, discusses translational research efforts that have been made with targeting leukemia stem cells and ongoing clinical trials that are examining novel therapeutic targets in myeloid malignancies and beyond.

Jonathan L. Kaufman, MD, discusses the significance of subcutaneous D-VCd in the treatment of patients with AL amyloidosis, remaining questions with the approach, and emerging strategies for those with high-risk cardiac features.

Somatic KMT2A rearrangements, RAS/MAPK mutations, RUNX1 and TP53 alterations, and MECOM overexpression were all found to be common oncogenic drivers of pediatric therapy-related myeloid neoplasms, arising predominantly after exposure to cytotoxic therapy and identifiable at least 1 year prior to morphologic evidence of neoplasm.

Approaches to sequencing therapy for patients with follicular lymphoma who experience progression of disease within 24 months (POD24).

An overview of novel therapies under investigation for the treatment of relapsed/refractory follicular lymphoma and special considerations regarding treating patients with newer, novel agents in the community setting.

The addition of narsoplimab to human serum significantly inhibited the formation of C5b-9 and platelet thrombi on human microvascular endothelial cells in 3 patients with acute hematopoietic stem cell transplant – or bone marrow transplant –associated thrombotic microangiopathy.

A simplified geriatric assessment offers a validated objective tool to assess fitness status and should be considered the new Elderly Prognostic Index standard to predict overall survival in older patients with diffuse large B-cell lymphoma.

The multitumor-associated antigen-specific T-cell product MT-401 is under investigation as a potential treatment option for patients with acute myeloid leukemia following allogeneic stem cell transplant in both the adjuvant and active disease settings.

Digital media, now more than ever, has become a primary platform for communication, and in 2020, the production of the OncLive® podcast, OncLive On Air™, was put into overdrive to bring practicing oncologists exclusive biweekly interviews, discussions, and insights from leading experts in cancer care.

Mehrdad Abedi, MD, discusses the challenges of standard transplant, how Orca-T could overcome some of those limitations, and the potential future of transplant in hematologic malignancies.

Jeffrey Laurence, MD, reviews the risk factors for developing transplant-associated thrombotic microangiopathy, and the panel discusses how risk affects their decision to change or modify treatment regimens.

Parameswaran Hari, MD, and Christine Duncan, MD, discuss the differences between uncontrolled vs self-limited transplant-associated thrombotic microangiopathy.

Insight regarding the assessment of the prevalence of FLT3-ITD versus FLT3-TKD mutations and allelic burden in newly diagnosed acute myeloid leukemia.

Jessica K. Altman, MD, and Naval G. Daver, MD, share their approaches to genetic testing for FLT3 and other actionable mutations in acute myeloid leukemia (AML).

A review of data from the COMFORT trials and the management and real-world use of ruxolitinib in patients with myelofibrosis, also touching on its use during the coronavirus pandemic.

Srdan Verstovsek, MD, PhD, reviews data from the JAKARTA and JAKARTA2 clinical trials as well as his approach to using fedratinib in his own clinical practice.